{
  "schemaVersion": 1,
  "organisationId": "O-58496e0980af46f9a9e5b800970fa005",
  "slug": "tarsus-pharmaceuticals-inc",
  "name": "Tarsus Pharmaceuticals, Inc.",
  "updatedAt": "2026-10-02T13:59:10.862251Z",
  "sections": [
    {
      "type": "OVERVIEW",
      "text": "Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutics, starting with eye care. Its marketed product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, is approved in the United States to treat Demodex blepharitis; its pipeline also includes investigational programs in ocular rosacea and infectious disease prevention. [P147596764][P147597220] The company’s stated mission is “Serving patient needs is our passion; delivering revolutionary treatments is our mission.” [https://tarsusrx.com/our-story/]\n\nTarsus has a U.S.-centered commercial presence and announced a Greater China development and commercialization partnership for TP-03. [https://ir.tarsusrx.com/news-releases/news-release-details/tp-03-lotilaner-ophthalmic-solution-025-now-approved-china] For scale, it reported $335.966 million in total revenue for the six months ended June 30, 2026, and 370 full-time employees as of December 31, 2025. [T16891482][P4277214]\n[P147596764][P147597220][https://tarsusrx.com/our-story/][https://ir.tarsusrx.com/news-releases/news-release-details/tp-03-lotilaner-ophthalmic-solution-025-now-approved-china][T16891482][P4277214][https://tarsusrx.com/our-story/][https://ir.tarsusrx.com/news-releases/news-release-details/tp-03-lotilaner-ophthalmic-solution-025-now-approved-china]",
      "updatedAt": "2026-10-02T13:59:10.862251Z"
    },
    {
      "type": "PRODUCTS",
      "text": "Tarsus Pharmaceuticals’ marketed product is XDEMVY® (lotilaner ophthalmic solution) 0.25%, an FDA-approved treatment for Demodex blepharitis. Lotilaner is designed to paralyze and eradicate mites by inhibiting parasite-specific GABA-Cl channels. [P10022446][P22352579] XDEMVY was the company’s only marketed product in the reviewed disclosures. [P147596968]\n\nIts investigational pipeline includes TP-04, a lotilaner-based sterile aqueous ophthalmic gel being studied for ocular rosacea, and TP-05, an oral lotilaner tablet being developed for Lyme disease prophylaxis and community malaria reduction. Both programs were in Phase 2, according to the company’s 2026 second-quarter filing. [P147596784][P147596768][P147596767][P147596769] The company also acquired IRX-101 in July 2026: a stable aqueous chlorine dioxide solution under development as an ocular antiseptic intended to reduce post-procedural pain and corneal toxicity in patients receiving intravitreal therapy. [P147596770][P147596796]\n\nNet product sales were $319.299 million in the first half of 2026, about 95% of total revenue of $335.966 million; the filing identifies XDEMVY as the company’s only marketed product. [T16891482][P147596968] The reviewed disclosures do not describe separate service offerings.\n[P10022446][P22352579][P147596968][P147596784][P147596768][P147596767][P147596769][P147596770][P147596796][T16891482]",
      "updatedAt": "2026-10-02T13:59:10.862251Z"
    },
    {
      "type": "GEOGRAPHY",
      "text": "Tarsus Pharmaceuticals is headquartered in Irvine, California; its principal executive office is listed at 17700 Laguna Canyon Road, Floor 4, Irvine, California 92618. The company relocated its headquarters in April 2026. [T16891475][P147596522] Its commercial product XDEMVY is sold in the United States. The company reports product sales without a country or regional breakdown, so geographic revenue percentages are not available. [P28293718][P147596294][T16891503]\n\nTarsus licensed TP-03 rights in China to GrandPharma; China is therefore a partner territory, not evidence of direct Tarsus sales. GrandPharma received approval in mainland China in March 2026, triggering a milestone payment to Tarsus. The company has also described exploring development and commercialization opportunities in Europe and Japan, but these are not identified as current sales markets. [P14679534][P147596670][P147596858] Tarsus does not operate its own manufacturing facilities and relies on third parties for commercial and clinical/preclinical manufacturing. [P110321017] No geographic breakdown of employees is disclosed in the reviewed filings.\n[T16891475][P147596522][P28293718][P147596294][T16891503][P14679534][P147596670][P147596858][P110321017]",
      "updatedAt": "2026-10-02T13:59:10.862251Z"
    },
    {
      "type": "SEGMENTS",
      "text": "Tarsus Pharmaceuticals reports one operating and reportable segment, **therapeutics**, and manages its business on an aggregated basis rather than reporting separate commercial or research-and-development segments. The segment’s activities primarily include U.S. sales of XDEMVY through specialty pharmacies and distributors, as well as license and collaboration revenue from its China out-license. It therefore represents approximately **100% of reported segment revenue**. [P147596587]\n\nThe single-segment structure is consistent with the company’s 2024 reporting. [P88559405]\n[P147596587][P88559405]",
      "updatedAt": "2026-10-02T13:59:10.862251Z"
    },
    {
      "type": "HISTORY",
      "text": "Tarsus Pharmaceuticals was founded in November 2016 by Bobak (“Bobby”) Azamian and Michael Ackermann. Azamian became president and chief executive officer in September 2018. [P28293718][P57760945] The company completed its initial public offering on October 20, 2020, selling shares at $16 each. [P177625372]\n\nA major development in Tarsus’s history was its clinical program for TP-03, later named XDEMVY: the drug met primary and secondary endpoints in the Saturn-1 Phase 2b/3 trial in June 2021, and in the Saturn-2 Phase 3 trial in 2022. [P173613221][P15803685] The FDA accepted the company’s new drug application in November 2022 and approved XDEMVY for Demodex blepharitis in July 2023; Tarsus launched the product the following month. [P111610095][P75988479]\n\nIn 2026, Tarsus expanded beyond its existing portfolio through acquisitions. It completed the acquisition of iRenix Medical, adding the investigational retina asset IRX-101, and acquired Alkeus Pharmaceuticals, gaining worldwide rights to investigational ALK-001. [https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-advances-eye-care-leadership-strategy-acquisition-irenix/][https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-pharmaceuticals-completes-acquisition-alkeus]\n[P28293718][P57760945][P177625372][P173613221][P15803685][P111610095][P75988479][https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-advances-eye-care-leadership-strategy-acquisition-irenix/][https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-pharmaceuticals-completes-acquisition-alkeus][https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-advances-eye-care-leadership-strategy-acquisition-irenix/][https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-pharmaceuticals-completes-acquisition-alkeus]",
      "updatedAt": "2026-10-02T13:59:10.862251Z"
    }
  ],
  "sources": [
    {
      "id": "P147596764",
      "href": "https://app.finbar.com/go?id=P147596764",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-18954cfd7ce1447fb6609fb5efd3917e"
    },
    {
      "id": "P147597220",
      "href": "https://app.finbar.com/go?id=P147597220",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-18954cfd7ce1447fb6609fb5efd3917e"
    },
    {
      "id": "https://tarsusrx.com/our-story/",
      "href": "https://tarsusrx.com/our-story/",
      "label": "tarsusrx.com"
    },
    {
      "id": "https://ir.tarsusrx.com/news-releases/news-release-details/tp-03-lotilaner-ophthalmic-solution-025-now-approved-china",
      "href": "https://ir.tarsusrx.com/news-releases/news-release-details/tp-03-lotilaner-ophthalmic-solution-025-now-approved-china",
      "label": "ir.tarsusrx.com"
    },
    {
      "id": "T16891482",
      "href": "https://app.finbar.com/go?id=T16891482",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-18954cfd7ce1447fb6609fb5efd3917e"
    },
    {
      "id": "P4277214",
      "href": "https://app.finbar.com/go?id=P4277214",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2025 Y)",
      "documentId": "D-2a6893494b3e4ed0897cc8b711d9ae91"
    },
    {
      "id": "P10022446",
      "href": "https://app.finbar.com/go?id=P10022446",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2025 Y)",
      "documentId": "D-2a6893494b3e4ed0897cc8b711d9ae91"
    },
    {
      "id": "P22352579",
      "href": "https://app.finbar.com/go?id=P22352579",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2025 Y)",
      "documentId": "D-2a6893494b3e4ed0897cc8b711d9ae91"
    },
    {
      "id": "P147596968",
      "href": "https://app.finbar.com/go?id=P147596968",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-18954cfd7ce1447fb6609fb5efd3917e"
    },
    {
      "id": "P147596784",
      "href": "https://app.finbar.com/go?id=P147596784",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-18954cfd7ce1447fb6609fb5efd3917e"
    },
    {
      "id": "P147596768",
      "href": "https://app.finbar.com/go?id=P147596768",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-18954cfd7ce1447fb6609fb5efd3917e"
    },
    {
      "id": "P147596767",
      "href": "https://app.finbar.com/go?id=P147596767",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-18954cfd7ce1447fb6609fb5efd3917e"
    },
    {
      "id": "P147596769",
      "href": "https://app.finbar.com/go?id=P147596769",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-18954cfd7ce1447fb6609fb5efd3917e"
    },
    {
      "id": "P147596770",
      "href": "https://app.finbar.com/go?id=P147596770",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-18954cfd7ce1447fb6609fb5efd3917e"
    },
    {
      "id": "P147596796",
      "href": "https://app.finbar.com/go?id=P147596796",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-18954cfd7ce1447fb6609fb5efd3917e"
    },
    {
      "id": "T16891475",
      "href": "https://app.finbar.com/go?id=T16891475",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-18954cfd7ce1447fb6609fb5efd3917e"
    },
    {
      "id": "P147596522",
      "href": "https://app.finbar.com/go?id=P147596522",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-18954cfd7ce1447fb6609fb5efd3917e"
    },
    {
      "id": "P28293718",
      "href": "https://app.finbar.com/go?id=P28293718",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2025 Y)",
      "documentId": "D-2a6893494b3e4ed0897cc8b711d9ae91"
    },
    {
      "id": "P147596294",
      "href": "https://app.finbar.com/go?id=P147596294",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-18954cfd7ce1447fb6609fb5efd3917e"
    },
    {
      "id": "T16891503",
      "href": "https://app.finbar.com/go?id=T16891503",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-18954cfd7ce1447fb6609fb5efd3917e"
    },
    {
      "id": "P14679534",
      "href": "https://app.finbar.com/go?id=P14679534",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2025 Y)",
      "documentId": "D-2a6893494b3e4ed0897cc8b711d9ae91"
    },
    {
      "id": "P147596670",
      "href": "https://app.finbar.com/go?id=P147596670",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-18954cfd7ce1447fb6609fb5efd3917e"
    },
    {
      "id": "P147596858",
      "href": "https://app.finbar.com/go?id=P147596858",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-18954cfd7ce1447fb6609fb5efd3917e"
    },
    {
      "id": "P110321017",
      "href": "https://app.finbar.com/go?id=P110321017",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2025 Y)",
      "documentId": "D-2a6893494b3e4ed0897cc8b711d9ae91"
    },
    {
      "id": "P147596587",
      "href": "https://app.finbar.com/go?id=P147596587",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-18954cfd7ce1447fb6609fb5efd3917e"
    },
    {
      "id": "P88559405",
      "href": "https://app.finbar.com/go?id=P88559405",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2024 Y)",
      "documentId": "D-f163852dcbaa45c2b4f0b33feb4a65f8"
    },
    {
      "id": "P57760945",
      "href": "https://app.finbar.com/go?id=P57760945",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2025 Y)",
      "documentId": "D-2a6893494b3e4ed0897cc8b711d9ae91"
    },
    {
      "id": "P177625372",
      "href": "https://app.finbar.com/go?id=P177625372",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2020 Y)",
      "documentId": "D-f6980ce354d44afdbf6d3a466bd8e5a6"
    },
    {
      "id": "P173613221",
      "href": "https://app.finbar.com/go?id=P173613221",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2021 Q 2)",
      "documentId": "D-ba68ce06c9f746e9944d4aa2296f6e35"
    },
    {
      "id": "P15803685",
      "href": "https://app.finbar.com/go?id=P15803685",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2022 Q 2)",
      "documentId": "D-f4e4e17343b24efd8a63de59ffd379d0"
    },
    {
      "id": "P111610095",
      "href": "https://app.finbar.com/go?id=P111610095",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2022 Q 3)",
      "documentId": "D-a96babb35c1b4e39944604f940be6df6"
    },
    {
      "id": "P75988479",
      "href": "https://app.finbar.com/go?id=P75988479",
      "label": "Tarsus Pharmaceuticals, Inc. — Full financial report (2023 Q 3)",
      "documentId": "D-9c347235e4314b59a3720e8ce57efeb0"
    },
    {
      "id": "https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-advances-eye-care-leadership-strategy-acquisition-irenix/",
      "href": "https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-advances-eye-care-leadership-strategy-acquisition-irenix/",
      "label": "ir.tarsusrx.com"
    },
    {
      "id": "https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-pharmaceuticals-completes-acquisition-alkeus",
      "href": "https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-pharmaceuticals-completes-acquisition-alkeus",
      "label": "ir.tarsusrx.com"
    }
  ]
}